Grant Seeker Grant Recipient
Alliance Against HMERF, Inc. SILVER VISIBILITY TIER™ badge #1602239
This organization has achieved the
GrantWatch SILVER VISIBILITY TIER™
Organizations Alliance Against HMERF, Inc.

Alliance Against HMERF, Inc.

The Alliance Against HMERF, Inc. is a nonprofit organization dedicated to accelerating scientific discovery and advancing therapeutic development for Hereditary Myopathy with Early Respiratory Failure (HMERF), an ultra-rare and progressive form of muscular dystrophy. Born from one family's personal journey and supported by so many other similar stories, Alliance Against HMERF is driven by a global vision to fund groundbreaking research, connect the patient community, and champion awareness to ensure that no one faces this disease alone.

Source: Provided by the organization
Public Charity 501(c)(3) NTEE G50

Official GrantWatch Organization Profile

Profile Claimed Profile Verified Website Verified

This organization has successfully claimed and verified its official GrantWatch profile.

https://www.fighthmerf.org

Silver
VISIBILITY TIER™
Verified:
July 14, 2026
Badge ID:
GW-SI-0000094
Take Action on GrantWatch
Find Related Grants

Your pipeline and saved activity stay private to your GrantWatch account.

MemberPlus+ unlocks the full 990 profile Financials, grant recipients, officers & downloadable IRS reports.
Upgrade

Organization Overview

Street address
LAGRANGE, GA 30241-8834
EIN
MemberPlus+
Earliest Filing
2024
Organization Type
Public Charity
Deductibility Status
Contributions are tax-deductible

Grants Received by Year

This organization is a grant recipient. See Funding Received below for details.

HighMediumLow
Low
2021
Total Grants Received
$X.XB
All Years
Filings on File
1
Tax Years
NTEE Category
G50
Nerve, Muscle & Bone Diseases

IRS Classification Codes

NTEE Code
G50
Nerve, Muscle & Bone Diseases

The National Taxonomy of Exempt Entities (NTEE) code is a four digit code used to classify an exempt IRC 501(c)(3) organization.

Subsection Code
03
Private operating foundation (other)

Subsection Codes are the codes shown under section 501(c) of the Internal Revenue Code of 1986 which define the category under which an organization may be exempt.

Asset Code
0
0

Asset Codes relate to the amount of assets shown on the most recent Form 990 series return filed by the organization.

Affiliation Code
3
Independent - This code is used if the organization is an independent organization or an independent auxiliary (i.e., not affiliated with a National, Regional, or Geographic grouping of organizations).

Affiliation Code defines the organizational grouping.

Deductibility Code
1
Contributions are deductible.

Deductibility Code signifies whether contributions made to an organization are deductible.

Documents

These documents are available to GrantWatch MemberPlus members. Upgrade to view.

IRS Form 990/990PF, 990N or Publication 78 Data PDF

Funding Received

Verified from IRS Form 990 Schedule I filings by this organization's funders - 1 grant from 1 funder, 2021.

Funders, amounts, and purposes are available to GrantWatch MemberPlus members. Upgrade to view.

Source: Provided by the organization

About the Organization

Organization category
Public Charity
Mission
The Alliance Against HMERF, Inc. is a nonprofit organization dedicated to accelerating scientific discovery and advancing therapeutic development for Hereditary Myopathy with Early Respiratory Failure (HMERF), an ultra-rare and progressive form of muscular dystrophy. Born from one family's personal journey and supported by so many other similar stories, Alliance Against HMERF is driven by a global vision to fund groundbreaking research, connect the patient community, and champion awareness to ensure that no one faces this disease alone.
Programs or services
Alliance Against HMERF's sole financial focus is on developing a medical treatment for HMERF muscular dystrophy. To date, we have funded >$250,000 in medical research and we're half way there. We have also created communities where HMERF patients can talk and share their stores.
Detailed programs
Developed an ASO targeting the damaged exon on the titin protein chain and completed Stage 1 testing with a proof-of-concept outcome.
Target Audience
Hereditary Myopathy with Early Respiratory Failure; Myofibular Myopathy 9
Geographic Focus
Global
Current projects
Seeking funding for Stage 2 research to identify efficacy and toxicity of our proof-of-concept ASO.
Organization goals
Our goal is simple and clear: find a treatment to slow, stop and ultimately restore damaged muscle tissue created by damage to an exon on the titin protein chain.
Leadership
Christine Garner-Duane, CEO/Ex. Director: chris.duane@fighthmerf.og
Rodney Bowling Jr, PhD, Chief Science officer, Alpharose Labs: rodney@alpharose.com

Funding Needs

Funding needs
Stage 2 funding: ~$85,000 to conduct organoid testing for efficacy and toxicity of our ASO.